Xenetic Biosciences, Inc. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Xenetic Biosciences (market cap ~$5.1M) announced a definitive share exchange agreement to acquire Santersus AG in an all-stock transaction expected to close Q1 2027, creating a Nasdaq-listed clinical-stage company focused on targeting neutrophil extracellular traps (NETs). The combined entity will be named Santersus Bio, Inc. (ticker: SNTS) and will combine Xenetic's DNase platform with Santersus's NucleoCapture platform, including four first-in-class programs with two FDA Breakthrough Device Designations in sepsis and systemic lupus erythematosus. Q3 2026 financials showed royalty revenue of $0.7M (down 29% YoY), R&D expenses of $0.5M (down 31%), G&A expenses of $1.9M (up 138% due to transaction costs), net loss of $1.7M ($0.72/share), and cash of $5.8M.
Why this rating
Business-transforming reverse merger: $5.1M company merging with clinical-stage asset; fundamentally reshapes pipeline, pipeline ownership structure, and strategic focus; multiple clinical catalysts in 2027; survival-critical for micro-cap.
Tradability signal
NO TRADE
No trade: only ~$33k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.66 | +10 min · unknown $1.66 ▲ 0.00% | +30 min · unknown $1.66 ▲ 0.00% | +1 hr · unknown $1.84 ▲ 10.66% | +4 hrs · unknown $1.72 ▲ 3.67% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.